Statin Therapy in Very Old Patients: Lights and Shadows

  1. Cobos-Palacios, Lidia
  2. Sanz-Cánovas, Jaime
  3. Muñoz-Ubeda, Mónica
  4. Lopez-Carmona, María Dolores
  5. Perez-Belmonte, Luis Miguel
  6. Lopez-Sampalo, Almudena
  7. Gomez-Huelgas, Ricardo
  8. Bernal-Lopez, Maria Rosa
Revista:
Frontiers in Cardiovascular Medicine

ISSN: 2297-055X

Año de publicación: 2021

Volumen: 8

Tipo: Artículo

DOI: 10.3389/FCVM.2021.779044 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Frontiers in Cardiovascular Medicine

Resumen

Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death worldwide. High levels of total cholesterol—and of low-density lipoprotein cholesterol in particular—are one of the main risk factors associated with ASCVD. Statins are first-line treatment for hypercholesterolemia and have been proven to reduce major vascular events in adults with and without underlying ASCVD. Findings in the literature show that statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged people, but their benefits in older adults are not as well-established, especially in primary prevention. Furthermore, many particularities must be considered regarding their use in old subjects, such as age-related changes in pharmacokinetics and pharmacodynamics, comorbidities, polypharmacy, and frailty, which decrease the safety and efficacy of statins in this population. Myopathy and a possible higher risk of falling along with cognitive decline are classic concerns for physicians when considering statin use in the very old. Additionally, some studies suggest that the relative risk for coronary events and cardiovascular mortality associated with high levels of cholesterol decreases after age 70, making the role of statins unclear. On the other hand, ASCVD are one of the most important causes of disability in old subjects, so cardiovascular prevention is of particular interest in this population in order to preserve functional status. This review aims to gather the current available evidence on the efficacy and safety of statin use in very old patients in both primary and secondary prevention.

Referencias bibliográficas

  • Moran, (2014), Circulation., 129, pp. 1483, 10.1161/CIRCULATIONAHA.113.004042
  • Cholesterol, (2012), Lancet., 380, pp. 581, 10.1016/S0140-6736(12)60367-5
  • Saxon, (2016), Prog Cardiovasc Dis., 59, pp. 153, 10.1016/j.pcad.2016.07.009
  • Ward, (2019), Circ Res., 124, pp. 328, 10.1161/CIRCRESAHA.118.312782
  • 1950-2050 AgeingWP 2001
  • Collerton, (2009), BMJ., 339, pp. b4904, 10.1136/bmj.b4904
  • Yazdanyar, (2009), Clin Geriatr Med., 10.1016/j.cger.2009.07.007
  • Virani, (2021), Circulation., 143, pp. e254, 10.1161/CIR.0000000000000950
  • Marrugat, (2004), Eur J Epidemiol, 19, pp. 231, 10.1023/B:EJEP.0000020446.57845.b0
  • Benjamin, (2017), Circulation, 135, pp. e146, 10.1161/CIR.0000000000000491
  • Aslam, (2009), Clin Geriatr Med., 10.1016/j.cger.2009.08.001
  • Guallar-Castillón, (2012), Rev Esp Cardiol., 65, pp. 551, 10.1016/j.rec.2012.03.001
  • Ericsson, (1991), J Clin Invest., 87, pp. 591, 10.1172/JCI115034
  • Krumholz, (1994), JAMA., 272, pp. 1335, 10.1001/jama.272.17.1335
  • Schatz, (2001), Lancet., 358, pp. 351, 10.1016/S0140-6736(01)05553-2
  • Conroy, (2003), Eur Heart J, 24, pp. 987, 10.1016/S0195-668X(03)00114-3
  • Arnett, (2019), J Am Coll Cardiol, 74, pp. e177, 10.1016/j.jacc.2019.03.010
  • D'Agostino, (2008), Circulation., 117, pp. 743, 10.1161/CIRCULATIONAHA.107.699579
  • Ueda, (2017), Br J Gen Pract., 67, pp. e598, 10.3399/bjgp17X692141
  • Cooney, (2016), Eur J Prev Cardiol, 23, pp. 1093, 10.1177/2047487315588390
  • Kleipool, (2020), Heart., 106, pp. 261, 10.1136/heartjnl-2019-315600
  • Cruz, (2013), JAMA., 309, pp. 874, 10.1001/jama.2013.1184
  • Taylor, (2013), Cochrane Database Syst Rev., 2013, pp. CD004816, 10.1002/14651858.CD004816.pub5
  • Singh, (2018), J Am Geriatr Soc., 66, pp. 2188, 10.1111/jgs.15449
  • Kantor, (2015), JAMA., 314, pp. 1818, 10.1001/jama.2015.13766
  • Chokshi, (2012), Am J Cardiol., 110, pp. 1477, 10.1016/j.amjcard.2012.06.058
  • Koopman, (2013), Eur Heart J., 34, pp. 3198, 10.1093/eurheartj/eht368
  • Ko, (2004), JAMA., 291, pp. 1864, 10.1001/jama.291.15.1864
  • Wenger, (2004), Am J Geriatr Cardiol., pp. 4
  • Benner, (2002), JAMA., 288, pp. 455, 10.1001/jama.288.4.455
  • Perna, (2021), Eur Heart J Suppl., 10.1093/eurheartj/suab103
  • Maroo, (2008), Am J Geriatr Cardiol., 17, pp. 92
  • Magni, (2015), Eur J Intern Med., 26, pp. 82, 10.1016/j.ejim.2015.01.002
  • Rea, (2021), JAMA Netw Open., 4, pp. e2113186, 10.1001/jamanetworkopen.2021.13186
  • (2007), Ann Intern Med, 147, pp. 1, 10.7326/0003-4819-147-1-200707030-00002
  • Iwere, (2015), Br J Clin Pharmacol., 80, pp. 363, 10.1111/bcp.12687
  • Nanna, (2018), J Am Heart Assoc., 7, pp. e008546, 10.1161/JAHA.118.008546
  • Robinson, (2007), Aging Health., 3, pp. 691, 10.2217/1745509X.3.6.691
  • Ott, (2015), J Gen Intern Med., 30, pp. 348, 10.1007/s11606-014-3115-3
  • Samaras, (2019), J Am Coll Cardiol., 74, pp. 2554, 10.1016/j.jacc.2019.09.041
  • Zhou, (2021), J Am Coll Cardiol, 77, pp. 3145, 10.1016/j.jacc.2021.04.075
  • van, (2020), J Am Geriatr Soc., 68, pp. 417, 10.1111/jgs.16219
  • Mizera, (1998), Wiad Lek., pp. 52
  • Denke, (1990), Ann Intern Ed., 112, pp. 780, 10.7326/0003-4819-112-10-780
  • Lavan, (2017), Age Ageing, 46, pp. 600, 10.1093/ageing/afx005
  • Ouchi, (2019), Circulation., 140, pp. 992, 10.1161/CIRCULATIONAHA.118.039415
  • Zou, (2013), J Geriatr Cardiol., 10, pp. 349, 10.3969/j.issn.1671-5411.2013.04.014
  • Gurwitz, (2016), JAMA., 316, pp. 1971, 10.1001/jama.2016.15212
  • Shepherd, (2002), Lancet., 360, pp. 1623, 10.1016/S0140-6736(02)11600-X
  • Glynn, (2010), Ann Intern Med., 10.7326/0003-4819-152-8-201004200-00005
  • Yusuf, (2016), N Engl J Med, 374, pp. 2021, 10.1016/j.jvs.2016.07.054
  • Han, (2017), JAMA Intern Med, 177, pp. 955, 10.1001/jamainternmed.2017.1442
  • Ramos, (2018), BMJ., 362, pp. k3359, 10.1136/bmj.k3359
  • Orkaby, (2020), JAMA., 324, pp. 68, 10.1001/jama.2020.7848
  • Awad, (2021), BMC Med., 19, pp. 139, 10.1186/s12916-021-02009-1
  • Stone, (2019), Prog Cardiovasc Dis., 62, pp. 375, 10.1016/j.pcad.2019.11.005
  • Scandinavian, (1994), Lancet, 344, pp. 1383, 10.1016/S0140-6736(94)90566-5
  • Heart, (2002), Lancet, 360, pp. 7, 10.1016/S0140-6736(02)09327-3
  • Deedwania, (2007), Circulation., 115, pp. 700, 10.1161/CIRCULATIONAHA.106.654756
  • Cholesterol, (2019), Lancet, 393, pp. 407, 10.1016/S0140-6736(18)31942-1
  • Ponce, (2019), J Clin Endocrinol Metab., 104, pp. 1585, 10.1210/jc.2019-00195
  • Mach, (2020), Eur Heart J, 41, pp. 111, 10.1093/eurheartj/ehz455
  • Grundy, (2019), Circulation, 139, pp. e1082, 10.1161/CIR.0000000000000624